SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending as traders discuss its low float and potential for a short squeeze, drawing comparisons to other Hong Kong-based stocks that have recently seen significant gains. Community members are pointing to the company's regained NASDAQ compliance and a substantial contract that exceeds its market capitalization as potential catalysts. The high cost to borrow is also fueling speculation about a potential squeeze.

"What's Updog?" is a Community Led token.

UpDog

UpDog CRYPTO is trending, and the community is actively engaging with a playful, meme-driven narrative centered around the question, "What's UpDog?". Built on Solana, UpDog has a dedicated community, and some are highlighting its long-term presence in the meme coin space.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

$FIRECOIN is trending amid community discussions about potential scams and pump-and-dump schemes, with some users reporting difficulty selling. Despite the concerns, some traders are noting significant gains and momentum, particularly among Phantom Wallet users. Conversations often mention its association with the Solana blockchain.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

CVNA is trending amid discussions about the company's financial health and potential risks associated with subprime auto loans. Community members are debating the impact of rising delinquencies and the stability of Carvana's ABS deals, while some highlight insider selling and analyst ratings. The stock's high valuation and potential for a short squeeze are also being actively discussed.

The Next Big Secret. $NOWK is a stealthy, community-driven meme token on Solana. Be part of the exclusive early adoption stage and unlock the potential of this hidden gem.  NOWK is based on the viral meme No One Will Know which took the internet by storm! NOWK has something for everyone!  Everybody has something No One Will Know.  Your secrets are safe but not your MEMES! NOWK is the meme of memes!

NOWK

NOWK is trending amid community excitement surrounding its presence on Phantom Wallet. Early interest and perceived 'moon vibes' are fueling discussions, with many viewing it as a potential gem within the Solana ecosystem.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems ($DCTH) is trending as investors analyze CHOPIN trial data heading to #esmo2025. The community is weighing the potential for significant upside, buyout possibilities, and increased volatility. Some investors believe recent data shows the combination therapy had a significant increase in two-year survival.

Stonks is the first ever memecoin on the Solana blockchain.   Verifiably deployed in block 71935764 on April 02, 2021 22:10:10 UTC.  On 2024-11-24 members of the community banded together and purchased the website, Twitter, GitHub and developer coins from the original team, making it 100% community owned.  Liquidity has been locked and the community is committed to ensuring the revival of the project

Stonks

Stonks ($STNK) is trending as the first memecoin on Solana, backed by the IP rights to the iconic "Stonks" meme, and is gaining attention amidst the current meme coin season. The community emphasizes its provenance and unique position as the original meme coin on Solana, with some anticipating a rise to 1 $STNK = 1 $ETH. Community members highlight the token's strong community and proven ability to survive a community takeover.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders discuss potential volatility events and market manipulation, with some anticipating a spike while others advocate shorting. Community members are weighing the potential for profit against the ETF's decay and the risks of holding it long-term. The ETF's behavior relative to SPY and VIX movements is also under scrutiny.

Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Solana Co. - Ordinary Shares - Class A

Solana Co

HSDT is trending due to a recent announcement of a $500M funding round to launch a Solana-backed treasury, sparking significant volatility and mixed reactions from traders. Community members are debating whether this move will be a game-changer or a dilution trap, while also watching for potential short squeezes and FDA catalyst news. The stock is seeing both bullish and bearish sentiment, with some eyeing price targets, while others cite concerns about dilution and the company's history.

SPX6900 is an advanced blockchain cryptography token coin capable of limitless possibilities and scientific utilization.

SPX6900

SPX6900 is trending as community members highlight its potential for significant gains and compare it to early stages of other successful meme assets. There's a strong emphasis on community belief and long-term holding, with some suggesting it could "flip the stock market". Discussions also reference its performance relative to Bitcoin and other altcoins, noting potential listings and new ATH.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Analyst Reports for Home Depot, Boeing & Progressive

Analysts spotlight Home Depot, Boeing, and Progressive in today's top Zacks reports, revealing growth drivers, risks, and key performance trends.

Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know

Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.

Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?

JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation

Speaking at CNBC's Invest in America Forum, the CEOs said the U.S. still leads in many sectors, but inconsistent policy and underinvestment is ceding ground...

Pfizer (PFE) CEO Albert Bourla reportedly said on Wednesday that vaccines are harder to get approved while Health Secretary Robert F. Kennedy Jr. oversees the U.S. Food and Drug Administration.Kennedy Jr., a known vaccine skeptic, is currently attempting to overhaul vaccine policies in the U.S.“It’s not harder to get drug approvals right now. It’s harder to get vaccine approvals,” Bourla said at a CNBC event in Washington, as <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/pfizer-ceo-says-vaccine-approvals-are-harder-to-get-right-now">reported</a> by Bloomberg.The U.S. Food and Drug Administration under Kennedy Jr. in May said they would adopt a new COVID-19 vaccination regulatory framework, requiring new clinical trials to approve annual vaccine booster shots in healthy individuals under 65.The agency said that it will approve vaccines for high-risk persons such as adults 65 and older and individuals above the age of six months with risk factors putting them at high risk for severe infections, but demand “robust, gold-standard data” for healthy people under 65.The agency approved an updated version of a COVID-19 vaccine made by Pfizer and BioNTech in August, but only for use in senior adults as well as in younger individuals who are at risk of severe outcomes from the infection.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:589/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_1_00_03_PM_png_d8656d4532.webp" alt="PFE's Sentiment Meter and Message Volume as of 1:00 p.m. ET on Oct. 15, 2025 | Source: Stocktwits" width="589" height="61"><figcaption>PFE's Sentiment Meter and Message Volume as of 1:00 p.m. ET on Oct. 15, 2025 | Source: Stocktwits</figcaption></figure>On Tuesday, Bourla <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-urges-us-china-collaboration-in-pharma-stock-drops-for-7th-day-as-traders-dividend-payout/ch6nSZkR3ZK">spoke</a> at the National Committee on U.S.-China Relations Gala in New York and said that the U.S. pharmaceutical industry should work more collaboratively with China, whose “dramatic speed, cost and scale” have reshaped global drug development.Late last month, Pfizer also <a href="https://stocktwits.com/news-articles/markets/equity/trump-announces-pfizer-drug-pricing-deal-company-to-invest-70-billion-in-us-manufacturing/chDDgU5R39O">inked</a> a deal with the Trump administration, which features steep price cuts on several drugs and a $70 billion U.S. investment in return for a three-year exemption from the President’s pharmaceutical tariffs.PFE stock is down by 9% this year and by about 17% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-jumps-after-eric-jackson-calls-it-next-100-bagger-platform/ch6FG0MR3Nu">Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer CEO Reportedly Says Vaccine Approvals Getting Harder

According to a report from Bloomberg, Bourla said that it's harder to get vaccine approvals and not drug approvals. 

Equity

According to a report from Bloomberg, Bourla said that it's harder to get vaccine approvals and not drug approvals. 


Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?

Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.

Pfizer, Inc. CEO Albert Bourla said on Tuesday that the U.S. pharmaceutical industry should work more collaboratively with China, whose “dramatic speed, cost and scale” have reshaped global drug development.&nbsp;Speaking at the National Committee on U.S.-China Relations Gala in New York, Bourla said China’s biopharma ecosystem now represents about 30% of global drug development, with around 1,200 novel drug candidates in progress, up from just 60 a decade ago, according to a Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-says-us-pharma-industry-needs-collaborate-with-china-2025-10-15/">report</a>.Pfizer’s stock fell 0.9% to $24.52 on Tuesday, marking its seventh straight session of losses, before inching up 0.2% in after-hours trading.His comments come amid escalating trade tensions and new U.S. restrictions targeting Chinese pharmaceutical firms. The U.S. House of Representatives passed a bill last year seeking to curb business with China’s drugmakers, though it stalled in the Senate. A new version has since been reintroduced.Despite the policy friction, U.S. and European pharmaceutical companies continue to rely on China’s scale and efficiency to support innovation. Earlier this year, Pfizer agreed to license an experimental cancer therapy from China’s 3SBio Inc for $1.25 billion upfront and up to $4.8 billion in potential milestone payments.&nbsp;Bourla noted that Chinese biotech firms accounted for nearly one-third of all large-pharma licensing deals last year, and can recruit patients for clinical trials up to five times faster than U.S. companies.Pfizer’s comments come weeks after its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-announces-pfizer-drug-pricing-deal-company-to-invest-70-billion-in-us-manufacturing/chDDgU5R39O">new drug pricing deal</a> with the Trump administration, which features steep price cuts on several drugs and a $70 billion U.S. investment in exchange for a three-year tariff exemption under the TrumpRX platform.&nbsp;Analysts, including&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pfizer-stock-hits-9-month-high-analysts-dismiss-trump-drug-deal-retail-extremely-bullish/chCAxO3R3OI">Bank of America, BMO Capital, Cantor Fitzgerald, and Raymond James</a>, downplayed the financial impact, saying the agreement was largely symbolic, left earnings guidance unchanged, and could serve as a model for other drugmakers navigating policy pressures.Additionally, Pfizer (PFE) reported positive topline data from its Phase 3 HER2CLIMB-05 trial evaluating Tukysa (tucatinib) in combination with standard maintenance therapy for patients with HER2-positive metastatic breast cancer on Tuesday.&nbsp;The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 122% surge in 24-hour message volume.One user said they were unfazed by the ongoing slide, viewing current prices as a rare opportunity to buy an undervalued stock offering a 7% dividend and a long-term hold for their retirement portfolio.<stembedurl>https://stocktwits.com/Ladd220/message/632339846</stembedurl>Another user expressed frustration over the continued decline, noting they hold more than 600 call options and missed the recent rally, while adding that only niche sectors like rare earths, quantum, and nuclear seem to be performing well.<stembedurl>https://stocktwits.com/Moshtrader77/message/632323154</stembedurl><a href="https://stocktwits.com/symbol/PFE">Pfizer’s stock</a> has declined 2.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Pfizer CEO Albert Bourla leaves a meeting between CEOs and Senators to discuss Israel's war with Hamas on Capitol Hill on June 18, 2024. (Photo by Andrew Harnik/Getty Images)

Pfizer CEO Urges US-China Collaboration In Pharma; Stock Drops For 7th Day As Traders Hold For Dividend Payout

Bourla highlighted China’s rapid rise in global drug development, noting it now accounts for 30% of activity worldwide and recruits clinical trial patients far faster than the U.S.

R&D spending now can have big payoffs later for companies

Just how long have people been saying you have to spend money to make money"?Historians maintain that this particular proverb goes all that way back to the Roman playwright Titus Maccius Plautus, who...

CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?

CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

PFE
Pfizer Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PFE News

PFEPfizer Inc